Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-07-15
DOI
10.1186/s12967-023-04338-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lung cancer immunotherapy: progress, pitfalls, and promises
- (2023) Aritraa Lahiri et al. Molecular Cancer
- The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment
- (2023) Maik Luu et al. Cancers
- Multi-Omics Analysis Reveals Intratumor Microbes as Immunomodulators in Colorectal Cancer
- (2023) Zhi Liu et al. Microbiology Spectrum
- Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma
- (2022) Melissa Frizziero et al. CLINICAL CANCER RESEARCH
- A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
- (2022) Junyu Long et al. Genome Medicine
- Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
- (2022) Carlo Genova et al. Frontiers in Immunology
- Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
- (2022) Loïc Reppel et al. Journal for ImmunoTherapy of Cancer
- Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
- (2022) Amirali B. Bukhari et al. Frontiers in Oncology
- The translational challenges of precision oncology
- (2022) Oriol Pich et al. CANCER CELL
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2022) Jie Wang et al. LANCET ONCOLOGY
- Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond
- (2022) Atena Soleimani et al. LIFE SCIENCES
- Gut microbes as biomarkers of ICI response — sharpening the focus
- (2022) Neal Bhutiani et al. Nature Reviews Clinical Oncology
- Small cell lung cancer: Novel treatments beyond immunotherapy
- (2022) Job-Joris Meijer et al. SEMINARS IN CANCER BIOLOGY
- WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
- (2022) Hirokazu Taniguchi et al. Cell Reports
- Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report
- (2022) Zibo Zhang et al. Frontiers in Oncology
- Pulmonary Neuroendocrine Cells and Small Cell Lung Carcinoma: Immunohistochemical Study Focusing on Mechanisms of Neuroendocrine Differentiation
- (2022) Takaaki Ito et al. ACTA HISTOCHEMICA ET CYTOCHEMICA
- Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
- (2022) Xiaomeng Yin et al. SEMINARS IN CANCER BIOLOGY
- Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer
- (2022) Sarah M. Groves et al. Cell Systems
- Resistance to systemic immune checkpoint inhibition in the peritoneal niche
- (2022) Daryl Kai Ann Chia et al. Journal for ImmunoTherapy of Cancer
- Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies
- (2022) Haiyong Wang et al. CANCER SCIENCE
- Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial
- (2022) Penella Woll et al. LUNG CANCER
- Transcriptional Profiling Reveals Mesenchymal Subtypes of Small Cell Lung Cancer with Activation of the Epithelial-to-Mesenchymal Transition and Worse Clinical Outcomes
- (2022) Hae Jin Cho et al. Cancers
- DLL3 regulates Notch signaling in small cell lung cancer
- (2022) Jun W. Kim et al. iScience
- Targeting the DNA Damage Response Machinery for Lung Cancer Treatment
- (2022) Katharigatta N. Venugopala Pharmaceuticals
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- (2021) Carl M. Gay et al. CANCER CELL
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- (2021) Stephen V. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Morphologic and molecular classification of lung neuroendocrine neoplasms
- (2021) Jasna Metovic et al. VIRCHOWS ARCHIV
- CAR T cells in solid tumors: challenges and opportunities
- (2021) Faroogh Marofi et al. Stem Cell Research & Therapy
- Small-cell lung cancer
- (2021) Charles M. Rudin et al. Nature Reviews Disease Primers
- Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
- (2021) D.R. Spigel et al. ANNALS OF ONCOLOGY
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
- (2021) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study
- (2021) Fiona Blackhall et al. Journal of Thoracic Oncology
- Molecular profiles of small cell lung cancer subtypes: therapeutic implications
- (2021) Anna Schwendenwein et al. Molecular Therapy-Oncolytics
- Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
- (2021) Selina K. Wong et al. Cancers
- PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
- (2021) Erik H. Knelson et al. Cancers
- Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
- (2021) Anish Thomas et al. CANCER CELL
- Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
- (2021) Ying Gong et al. Journal of Hematology & Oncology
- Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes
- (2021) Christina M. Bebber et al. Nature Communications
- Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features
- (2021) Wang Jin et al. Biomed Research International
- Small cell lung cancer: a slightly less orphan disease after immunotherapy
- (2021) J. Remon et al. ANNALS OF ONCOLOGY
- Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes
- (2021) M. Alper Kursunel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer
- (2021) Yun Jung Choi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Overcoming Chemotherapy Resistance in SCLC
- (2021) Brett H. Herzog et al. Journal of Thoracic Oncology
- Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer
- (2021) Huaqiang Zhou et al. Nature Communications
- Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
- (2021) Eiko Hayase et al. Genome Medicine
- Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway
- (2021) Cong Hou et al. FEBS Open Bio
- Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
- (2021) Joseph M. Chan et al. CANCER CELL
- Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
- (2021) Hanbing Wang et al. CANCER LETTERS
- Targeting cancer metabolism in the era of precision oncology
- (2021) Zachary E. Stine et al. NATURE REVIEWS DRUG DISCOVERY
- Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer
- (2021) Ming Chen et al. Nature Communications
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
- (2021) Everett J. Moding et al. Cancer Discovery
- Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer
- (2021) Erika Rijavec et al. Expert Review of Respiratory Medicine
- Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
- (2021) Xue-lin Zou et al. Frontiers in Immunology
- YAP drives fate conversion and chemoresistance of small cell lung cancer
- (2021) Qingzhe Wu et al. Science Advances
- SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
- (2021) Kiran Kundu et al. Translational Lung Cancer Research
- The MEK5-ERK5 kinase axis controls lipid metabolism in small cell lung cancer
- (2020) Sandra Cristea et al. CANCER RESEARCH
- Immune-resistant mechanisms in cancer immunotherapy
- (2020) Yutaka Kawakami et al. International Journal of Clinical Oncology
- Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
- (2020) Ole-Johan Skrede et al. LANCET
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and TLSs facilitate a response to ICI
- (2020) Diana Romero Nature Reviews Clinical Oncology
- Immunotherapeutic approaches for small-cell lung cancer
- (2020) Wade T. Iams et al. Nature Reviews Clinical Oncology
- Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
- (2020) Elaine Kilgour et al. CANCER CELL
- Acquired Resistance to Immune Checkpoint Inhibitors
- (2020) Adam J. Schoenfeld et al. CANCER CELL
- Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer
- (2020) Brianna Hoffner et al. CANCER TREATMENT REVIEWS
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineering CAR-T Cells for Next-Generation Cancer Therapy
- (2020) Mihe Hong et al. CANCER CELL
- Review of precision cancer medicine: Evolution of the treatment paradigm
- (2020) Apostolia M. Tsimberidou et al. CANCER TREATMENT REVIEWS
- Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer
- (2020) Sunny Z Wu et al. EMBO JOURNAL
- A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
- (2020) Andrea Ghelli Luserna di Rorà et al. Journal of Hematology & Oncology
- Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization
- (2020) Marina K. Baine et al. Journal of Thoracic Oncology
- Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
- (2020) Fang Huang et al. JOURNAL OF CLINICAL INVESTIGATION
- Liquid Biopsy in Small Cell Lung Cancer—A Route to Improved Clinical Care?
- (2020) Matt Church et al. Cells
- Predicting immunotherapy response through genomics
- (2020) Marina Candido Visontai Cormedi et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
- (2019) Remco Nagel et al. MOLECULAR CANCER THERAPEUTICS
- Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells
- (2019) Huanhuan Joyce Chen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival
- (2019) Patrick Kellish et al. JOURNAL OF CLINICAL INVESTIGATION
- DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer
- (2019) Sehhoon Park et al. Journal of Thoracic Oncology
- Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
- (2019) Re-I Chin et al. Molecular Diagnosis & Therapy
- MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
- (2019) Milind D. Chalishazar et al. CLINICAL CANCER RESEARCH
- Chemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer
- (2019) Jun Zhou et al. CURRENT MOLECULAR MEDICINE
- DLL3: an emerging target in small cell lung cancer
- (2019) Dwight H. Owen et al. Journal of Hematology & Oncology
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression
- (2019) Fanrui Zeng et al. ONCOGENE
- Cancer Stem Cells and Targeting Strategies
- (2019) Luisa Barbato et al. Cells
- CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
- (2019) Delong Liu Journal of Hematology & Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Identification of DHODH as a therapeutic target in small cell lung cancer
- (2019) Leanne Li et al. Science Translational Medicine
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
- (2019) Hyun Cheol Chung et al. Journal of Thoracic Oncology
- Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update
- (2019) Joseph A. Clara et al. Nature Reviews Clinical Oncology
- Circulating tumor DNA as an early cancer detection tool
- (2019) Andrea Campos-Carrillo et al. PHARMACOLOGY & THERAPEUTICS
- The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer
- (2018) Alice Lallo et al. CLINICAL CANCER RESEARCH
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
- (2018) Anish Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse
- (2018) Karinna Almodovar et al. Journal of Thoracic Oncology
- Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
- (2018) Kentaro Tanaka et al. LUNG CANCER
- Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models
- (2018) Denise L. Crossland et al. ONCOGENE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
- (2018) Benjamin J. Drapkin et al. Cancer Discovery
- Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening
- (2018) Anish Thomas et al. CHEST
- Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
- (2018) Alex H. Wagner et al. Nature Communications
- Targeting Cancer Stem Cells to Overcome Chemoresistance
- (2018) Toni Nunes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
- (2018) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting
- (2018) Win Sen Heng et al. BIOCHEMICAL PHARMACOLOGY
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- New development in CAR-T cell therapy
- (2017) Zhenguang Wang et al. Journal of Hematology & Oncology
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy
- (2017) Guifa Xi et al. Molecular Cancer
- A long non-coding RNA HOTTIP expression is associated with disease progression and predicts outcome in small cell lung cancer patients
- (2017) Yanqin Sun et al. Molecular Cancer
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
- (2017) Akane Inoue-Yamauchi et al. Nature Communications
- Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer
- (2017) Fabian Doerr et al. Scientific Reports
- Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
- (2017) M. Hardy-Werbin et al. OncoImmunology
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
- (2016) Manisha H. Shah et al. INVESTIGATIONAL NEW DRUGS
- Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
- (2016) Taofeek K. Owonikoko et al. Journal of Translational Medicine
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Cancer stem cell signaling pathways
- (2016) William H. Matsui MEDICINE
- Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
- (2016) Liyan Jiang et al. PLoS Genetics
- Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer
- (2016) Lynnette Fernandez-Cuesta et al. EBioMedicine
- Sonic Hedgehog in SCLC
- (2015) Mikko O. Laukkanen et al. Aging-US
- NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas
- (2015) Lydia Meder et al. INTERNATIONAL JOURNAL OF CANCER
- Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
- (2015) Tracey L. Evans et al. Journal of Thoracic Oncology
- The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung
- (2015) Adi F. Gazdar et al. Journal of Thoracic Oncology
- A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511)
- (2015) Taofeek K. Owonikoko et al. LUNG CANCER
- Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway
- (2015) Huanxin Liu et al. Molecular Cancer
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Regulation of HGF Expression by ΔEGFR-Mediated c-Met Activation in Glioblastoma Cells
- (2015) Jeannine Garnett et al. NEOPLASIA
- Small cell lung cancer: Where do we go from here?
- (2014) Lauren Averett Byers et al. CANCER
- Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
- (2014) Neelesh Sharma et al. INVESTIGATIONAL NEW DRUGS
- Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models
- (2014) Kathleen R Whiteman et al. mAbs
- Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis
- (2013) Ping Chen et al. MEDICAL ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis
- (2013) Toshiyuki Minami et al. Scientific Reports
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung
- (2011) Kate D. Sutherland et al. CANCER CELL
- Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
- (2011) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
- (2011) Amit K. Tiwari et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- (2011) Hiromichi Ebi et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
- (2011) Maria Q. Baggstrom et al. Journal of Thoracic Oncology
- Small-cell lung cancer
- (2011) Jan P van Meerbeeck et al. LANCET
- A crucial requirement for Hedgehog signaling in small cell lung cancer
- (2011) Kwon-Sik Park et al. NATURE MEDICINE
- Targeting apoptosis pathways in lung cancer
- (2010) Milind M. Pore et al. CANCER LETTERS
- Second-line chemotherapy for small-Cell Lung Cancer (SCLC)
- (2010) Young Hak Kim et al. CANCER TREATMENT REVIEWS
- Topotecan in the treatment of relapsed small cell lung cancer
- (2010) Elisabeth Quoix OncoTargets and Therapy
- Genetic changes in small cell lung carcinoma
- (2008) Edurne Arriola et al. Clinical & Translational Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started